Orbital fat atrophy in glaucoma patients treated with topical bimatoprost - Can bimatoprost cause enophthalmos?;Orbitale fettgewebsatrophie bei lokaler bimatoprost-therapie - Kann bimatoprost einen enophthalmus verursachen?

Klinische Monatsblatter fur Augenheilkunde

Volumn 225, Issue 5, 2008, Pages 443-445

  Tappeiner, Christoph ^a   Perren, B ^b   Iliev, M E ^a   Frueh, B E ^a   Goldblum, D ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b Privatpraxis ^*  (Switzerland)

^c UNIVERSITY EYE CLINIC   (Switzerland)

Author keywords

Adverse effect; Bimatoprost; Enophthalmos; Fat atrophy; Lumigan; Orbit; Prostamid

Indexed keywords

BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; PILOCARPINE; TIMOLOL;

AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC PROCEDURE; ENOPHTHALMOS; EXOPHTHALMOMETRY; EXTRACELLULAR MATRIX; EYELID; FIBROBLAST; GLAUCOMA; HERTEL EXOPHTHALMOMETRY; HUMAN; LID SULCUS; MEDICAL RECORD REVIEW; ORBIT; ORBITAL FAT ATROPHY; PATIENT; RETROSPECTIVE STUDY;

ADIPOSE TISSUE; ADMINISTRATION, TOPICAL; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; ATROPHY; CLOPROSTENOL; ENOPHTHALMOS; EYE; FEMALE; GLAUCOMA; HUMANS; MALE;

EID: 47649130467     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027362     Document Type: Article

References (14)

1. Ahmadi H et al. Age-related changes in the normal sagittal relationship between globe and orbit. J Plast Reconstr Aesthet Surg 2007; 3: 246-250
2. Chen Y, Du XY. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem 2007; 6: 1337-1345
3. Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging 2002; 3: 231-248
4. Fledelius HC. Exophthalmometry and thyroid disease. The value of the Hertel measurement evaluated by a group of patients with thyroid diseases and a control group. Ugeskr Laeger 1994; 44: 6528-6531
5. Grosskreutz CL, Paula JS, Pasquale LR. Periorbital Fat Loss and Eyelid Sulcus Deepening after Bimatoprost Therapy. 16th Annual Meeting of the American Glaucoma Society (AGS). 2 - 5.3.2006, Charleston Place, Charleston, South Carolina 2006: 53
6. Hamedani M, Pournaras JA, Goldblum D. Diagnosis and management of enophthalmos. Surv Ophthalmol 2007; 5: 457-473
7. Hollo G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf 2007; 1: 45-52
8. Kapur R et al. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol 2005; 11: 1541-1546
9. Liang Y et al. Comparison of prostaglandin F2alpha, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J Biol Chem 2003; 29: 27267-27277
10. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol 2002 Aug; 47 Suppl 1: S41-52
11. Mizuno K et al. Topical nipradilol: effects on optic nerve head circulation in humans and periocular distribution in monkeys. Invest Ophthalmol Vis Sci 2002; 10: 3243-3250
12. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 2004; 8: 574-577
13. Todorovicc V et al. The matrix protein CCN1 (CYR61) induces apoptosis in fibroblasts. J Cell Biol 2005; 3: 559-568
14. Vogel R, Strahlman E, Rittenhouse KD. Adverse events associated with commonly used glaucoma drugs. Int Ophthalmol Clin 1999; 2: 107-124